AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-9. (canceled)

preventing a mammal suffering from or at risk of suffering from obesity, being overweight, fluctuations in blood insulin levels or fluctuations in blood glucose levels in mammals, said method comprising enterally administering to [[a]] said mammal in need thereof an effective amount of a preparation containing glucose isomerase.

11. (canceled)

- 12. (previously presented) The method according to claim 10, wherein the preparation is provided with a coating that prevents reduction of activity of the enzyme by stomach acid and/or stomach proteases.
- 13. (previously presented) The method according to claim 10, wherein said enzyme is administered to the mammal during a period of 60 minutes before and 60 minutes after ingestion of a

Application No. 10/015,582
Amdt. Dated April 7, 2004
Reply to Office Action of October 7, 2003
Docket No. 2001-1208

carbohydrate and wherein the total amount of carbohydrate ingested during said period exceeds 5 grams.

14. (currently amended) The method according to claim 10, wherein the preparation further comprises one or more components selected from the group consisting of carbohydrate absorption inhibitors, carbohydrase inhibitors, and enzymes capable of synthesizing sparingly digestible saccharides from easily digestible saccharides, wherein the carbohydrase inhibitor is a plant derived polyphenol selected from the group consisting of catechins or derivatives thereof, anthocyanidins, procyanidins and cyanidins and combinations thereof, and wherein the carbohydrase absorption inhibitors are selected from the group consisting of gymnemic acid and soluble indigestible fibers.

15. (canceled)

16. (previously presented) The method according to claim 10, wherein the glucose isomerase has a pH optimum for converting glucose to fructose below pH 8.

17-18. (canceled)

Application No. 10/015,582
Amdt. Dated April 7, 2004
Reply to Office Action of October 7, 2003
Docket No. 2001-1208

19. (previously presented) The method according to claim 10, wherein the mammal is overweight or obese.

20. (new) A method of treating a mammal suffering from or at risk from suffering from obesity, being overweight, fluctuations in blood insulin levels or fluctuations in blood glucose levels in mammals, said method comprising enterally administering to said mammal in need thereof an effective amount of a preparation containing glucose isomerase, and wherein the glucose isomerase is administered at a level of 0.5 to 1500 international units (IU) enzyme per kilogram bodyweight of the mammal per dosage.

21. (new) A method of treating a mammal suffering from or at risk of suffering from obesity, being overweight, fluctuations in blood insulin levels, or fluctuations in blood glucose in mammals, said method comprising enterally administering to said mammal in need thereof an effective amount of a preparation containing glucose isomerase, and wherein said glucose isomerase is administered at a level of 10 to 100,000 international units (IU) per gram of dosage.